- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Lifesaver for Lost Exons
14 January 2003 (All day)
Many genetic diseases result from a small lapse: Cells ignore some sections of genes that encode protein. In the 13 January issue of Nature Structural Biology, Luca Cartegni and Adrian Krainer of New York's Cold Spring Harbor Laboratory describe a small molecule they've designed that prevents such mistakes. Test tube experiments suggest that the strategy may one day offer a novel route for treatment of these diseases.
The genetic instructions for making a protein in multicelled organisms such as humans aren't straightforward. Our genes are mosaics of protein-encoding DNA sections, called exons, separated by noncoding DNA. Cells first make an RNA copy of the DNA, then splice the exons together to form the final RNA template. To help guarantee correct splicing, short sequences within the exon RNA called ESEs--for exonic splicing enhancers--get tagged by so-called SR proteins. The tag fastens the exon to the molecular machinery responsible for splicing. If a mutation disrupts the ESE sequence, SR can't bind to it, and the exon gets left out of the RNA template.
To solve this problem, Cartegni and Krainer designed a hybrid molecule. At one end is an RNA-like tail designed to target the skipped exon; at the other end is a short string of amino acids, like those of SR for grabbing the splicing machinery.
As a prototype effort, Cartegni and Krainer designed the RNA-like end to bind the exon skipped in the mutant breast cancer gene BRCA1. Mixing labeled RNA copies of the defective gene with cell extracts produces spliced BRCA1 RNA templates that are one exon short. But even a pinch of the hybrid molecule allowed the mutant gene to generate the full-length RNA template, with all exons accounted for. The investigators then designed another hybrid molecule to target the skipped exon of SMN2, a gene involved in spinal muscular atrophy, and they had similar success.
Cartegni and Krainer's hybrid molecule is "an ingenious tool" that could have widespread clinical applications, says Ryszard Kole of the University of North Carolina, Chapel Hill. The next critical step, according to Kole, is to show that these molecules can be delivered into the cells and, more importantly, into living organisms.